Ascites or pleural effusion requiring intervention or that required intervention or recurred within three months prior to randomization
Pericardial effusion (except trace effusion identified by echocardiogram) within three months prior to randomization
No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Grade 3 or 4 thromboembolic event =< 6 months\r\n* Pericardial effusion =< 12 months (any grade)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 months
Patients must not have active pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray and echocardiogram within 28 days prior to registration; exception: if the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion =< grade 2 or pleural effusion =< grade 1
Patient has pleural effusion, ascites, or pericardial fluid requiring drainage Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligible
Have symptomatic ascites or pleural effusion.
Symptomatic ascites or pleural effusion.
Uncontrolled pleural effusion, pericardial effusion, or ascites
Symptomatic ascites or pleural effusion
Has ascites or pleural effusion by physical exam
Has symptomatic ascites or pleural effusion.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
Presence of fluid collection (ascites, pleural, or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.
Pleural or pericardial effusions of any grade at study entry; subjects previously diagnosed with pleural/pericardial effusion of any grade resolved at the time of study entry are allowed
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Concurrent medical condition that would increase drug toxicity: pleural or pericardial effusion, coagulation or platelet function disorder, ongoing or recent (less than 3 months gastrointestinal bleeding)
Presence of medically significant third space fluid (symptomatic pericardial effusion, ascites or pleural effusion requiring repetitive paracentesis)
Current, or history of a pericardial effusion, and/or hemodynamic compromise due to pericardial effusion of any size; minimal pericardial effusion < 50 cc is not excluded
Uncontrolled tumor-related pain; pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; or, hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) (patients with indwelling catheters such as PleurXÂ® are allowed)
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Symptomatic ascites or pleural effusion.
Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks prior to registration
Grade 2 or higher ascites, pleural, or pericardial effusion within 4 weeks of study enrollment or any history of recurrent grade 2 or higher effusions requiring ongoing drainage.
Ascites or pericardial effusion that required intervention within 3 months prior to study treatment
Uncontrolled pleural or pericardial effusion or ascites that would require recurrent drainage
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\r\n* Subjects with indwelling drainage catheters are allowed
Marked pleural effusion or ascites above Grade 2, based on NCI-CTCAE v4.03 criteria
No pleural or pericardial effusion of any grade
Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
Uncontrolled pleural or pericardial effusion or ascites that would require recurrent drainage
Symptomatic ascites or pleural effusion
Patients with any amount of clinically significant pericardial effusion
Pleural/pericardial effusion or ascites > 1 L
Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures >/=1 time per month
Has symptomatic ascites or pleural effusion
Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart
Has significant ascites or pleural effusion requiring drainage for symptom relief
Clinically detectable (by physical exam) third?space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
Uncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Ascites, pleural effusion or pericardial fluid requiring drainage in the last 4 weeks
Patients with pre-existing interstitial lung disease (ILD), or pericardial/pleural effusion of grade 2 or higher; trace pericardial or pleural effusion is acceptable
Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusion
Exclusion at the discretion of the principal investigator (PI) or delegate if participation to the study is deemed too risky (e.g. clinically significant pleural or pericardial effusion or ascites with possibly increased radio-toxicity)
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once monthly.
Significant ascites or pericardial or pleural effusion
Has symptomatic ascites or pleural effusion.
Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); participants with indwelling catheters are eligible
Subjects with ascites or pleural effusion requiring drainage within the last 28 days.
Symptomatic ascites or pleural effusion
Presence of a small (or greater size) pericardial effusion
No history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Pericardial effusion =< 12 months (grade 3 or 4)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 months
Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).
Uncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage catheters allowed)
Symptomatic ascites or pleural effusion
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Uncontrolled tumor-related pain or uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent (once monthly or more frequently) drainage procedures
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Presence of symptomatic pleural and/or pericardial effusion not appropriately treated
Presence of symptomatic pleural and/or pericardial effusion not appropriated treated
Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)
Patients with a pleural effusion requiring continuous drainage
Concurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any grade
Has symptomatic ascites or pleural effusion
Symptomatic pleural effusion (> CTCAE Grade 1 dyspnea) that is not amenable to drainage
Pleural effusion or ascites > 1 liter
Prior history of pericarditis or pericardial effusion
Clinically significant third-space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
Patients require regular ascites/pleural effusion drainage
Clinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.
Uncontrolled pleural effusion, pericardial effusion, or ascites
Patient with pleural effusion, ascites, or pericardial fluid requiring drainage.
Patient has pleural effusion, ascites, or pericardial fluid requiring drainage. Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligible.
Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequently
Uncontrolled clinical symptoms including pleural effusion, pericardial effusion, or ascites, tumor-related pain, hypercalcemia (or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy)
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
No effusion or ascites > 1 L prior to drainage
Uncontrolled pleural effusion or ascites
Signs of third spacing as determined by the treating physician (e.g., pedal edema, pleural effusion, ascites)
Uncontrolled pleural effusion, pericardial effusion, or ascites
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Malignant pleural effusion or pericardial effusion
Has symptomatic ascites or pleural effusion
Subjects with prior history of pericardial effusion or pleural effusion that required thoracentesis are excluded. Subjects with prior history of pericardial or pleural effusion that was clinically manageable and a maintained CMR for ? 1 year on a stable dose of dasatinib are allowed.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Significant pericardial effusion, pleural effusion, or ascites
